Letter to the Editor: Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data

Bipolar Disorders

Volumn 10, Issue 6, 2008, Pages 749-750

  Eppel, Alan B ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; LITHIUM; VALPROMIDE; ACETAMIDE DERIVATIVE; HYPNOTIC SEDATIVE AGENT;

AGITATION; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOMANIA; LETTER; MANIA; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ACUTE DISEASE; BIPOLAR DISORDER; NOTE; NURSING;

ACETAMIDES; ACUTE DISEASE; BIPOLAR DISORDER; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 49849105141     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2008.00586.x     Document Type: Letter

References (3)

1. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C, the Agomelatine Bipolar Study Group. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord 2007; 9: 628-635.
2. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537-1547.
3. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239.